Transcriptome Study of Acute Myocardial Infarction

Acute Myocardial Infarction Clinical Trial

Official title:

Screening Pathogenic Genes Associated With Acute Myocardial Infarction and Studying Its Relevant Molecular Mechanism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03158597
• Other study ID #: 5172011
• Status: Recruiting
• Phase: N/A
• First received: May 15, 2017
• Last updated: July 12, 2017
• Start date: June 1, 2017
• Est. completion date: December 31, 2019

Study information

• Verified date: July 2017
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to compare whole-blood microarray gene-expression profiling between patients with acute myocardial infarction and normal participants without cardiovascular diseases. Firstly, screening differentially genes of mRNA to perform gene ontology and pathway analysis. Secondly, predicting target genes regulated by microRNA and constructing coexpression network with mRNA. Thirdly, biological function experiment of microRNA. Finally, revealing pathogenic mechanisms associated with acute myocardial infarction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• AMI patients:

1. 20-50 years of age

2. Symptoms of ischaemia

3. New significant ST-segment-T wave changes in ECG and definitive diagnosis of non-ST elevation MI or ST elevation MI

4. Cardiac troponin with at least one value above the 99th percentile upper reference limit

• Normal control participants:

1. 20-50 years of age

2. Normal ECG

3. BMI <24kg/m2

4. systolic blood pressure <140mmHg

5. diastolic blood pressure <90mmHg

6. Total cholesterol <200mg/dl (5.18mmol/L)

7. Triglyceride <150mg/dl (1.70mmol/L)

8. High density lipoprotein cholesterol >=40mg/dl (1.04mmol/L)

9. Low density lipoprotein cholesterol <130mg/dl (3.37mmol/L)

10. Fasting blood glucose <100mg/dl (5.6mmol/L)

11. Not taking antihypertensive or hypolipidemic or hypoglycemic drugs

Exclusion Criteria:

1. Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased

2. Prior myocardial infarction

3. Percutaneous coronary intervention related MI

4. Stent thrombosis associated with MI

5. Coronary artery bypass grafting related MI

6. Recurrent MI or reinfarction

7. Myocardial injury with necrosis caused by transcatheter aortic valve implantation or mitral clip or ablation of arrhythmias

8. Myocardial injury or infarction associated with heart failure

9. Myocardial infarction in the intensive care unit

10. Other diseases: previous history of ASCVD, cancer, rheumatoid arthritis, liver or kidney disease, myeloproliferative disorders, chronic inflammation, peripheral vascular disease

11. Not available informed consent

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing	Chaoyang

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of screening differentially expressed genes associated with acute myocardial infarction as measured by microarray		up to 3 years